GLP-1 Agonists in Serious Mental Illness: Current Evidence

Psychopharmacology and Psychiatry Updates by Psychopharmacology Institute

Aug 29, 202615:27Health

In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psych...

Related Episodes

Continue listening to more episodes from Psychopharmacology and Psychiatry Updates.

SSRI Dosing for OCD: Beyond FDA Guidelines

Oct 3, 2026 - 09:10

Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 1.25 CME...

Trazodone for Insomnia and Comorbid Depression

Sep 28, 2026 - 10:57

In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautio...

Antipsychotics, Prolactin, and Sexual Side Effects

Sep 23, 2026 - 08:48

In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leadin...

EMERGENT-5: Cobenfy and Treatment Durability

Sep 18, 2026 - 12:55

In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial track...

Antipsychotics and Weight Gain

Sep 13, 2026 - 14:59

In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — w...

EPA vs. DHA: Fish Oil and Treatment-Resistant Depression

Sep 8, 2026 - 12:41

In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-...

AUD Medications and Hepatic Safety

Sep 3, 2026 - 10:14

In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin...

Gabapentin, Topiramate & Baclofen in AUD

Aug 24, 2026 - 17:22

In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate,...